Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Filippi

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Gastrointestinal Cancer|May 25, 2021
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Journal of Chemotherapy (Florence, Italy)|February 14, 2022
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancyMargherita Rimini, Andrea Casadei-Gardini, Giovanni Brandi, et al.
Journal of Gastrointestinal Cancer|February 5, 2021
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology|August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysisAlessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology|November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre StudyAlessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Clinical Colorectal Cancer|August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control StudyAlessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Gastrointestinal Cancer|May 25, 2021
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Journal of Chemotherapy (Florence, Italy)|February 14, 2022
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancyMargherita Rimini, Andrea Casadei-Gardini, Giovanni Brandi, et al.
Journal of Gastrointestinal Cancer|February 5, 2021
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology|August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysisAlessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology|November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre StudyAlessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Clinical Colorectal Cancer|August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control StudyAlessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Pageof 6